openPR Logo
Press release

Gram-Negative Bacterial Infection Market - Performance Survey 2025 | Takeda Pharmaceutical Company Limited, Nektar Therapeutics

04-01-2019 08:46 AM CET | Health & Medicine

Press release from: TMR Research

Gram-Negative Bacterial Infection Market - Performance Survey

Global Gram-Negative Bacterial Infection Market: Snapshot

Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94

The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.

According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.

Global Gram-negative Bacterial Infection: Overview

The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.

The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection market. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the gram-negative bacterial infection market.

Get TOC for Detailed Facts and Numbers @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94

Global Gram-negative Bacterial Infection: Infection-type Segmentation

On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.

Global Gram-negative Bacterial Infection: Analysis of Treatment Options

In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.

Global Gram-negative Bacterial Infection: Competitive Landscape

Players in the global gram-negative bacterial infection market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, gram-negative bacterial infection market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the gram-negative bacterial infection market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gram-Negative Bacterial Infection Market - Performance Survey 2025 | Takeda Pharmaceutical Company Limited, Nektar Therapeutics here

News-ID: 1680769 • Views: 402

More Releases from TMR Research

Gas Analyzer, Sensor and Detector Market Sluggish Growth Rate Foreseen by 2017-2 …
Gas Analyzer, Sensor and Detector Market: Snapshot Gas analyzers, sensors, and detectors have become a key part of several industries in recent years due to their effective contribution in averting mishaps related to gas leakage. The global gas analyzers, sensors, and detectors market is thus likely to grow at a steady rate in the coming years due to the rapid growth of the industrial sector across the world. Gas leakages can
Sustained Release Excipients Market Detailed Analysis and Forecast 2018-2028
Global Sustained Release Excipients Market: Overview The demand within the global sustained release excipients market has been rising on account of key improvements in the pharmaceutical industry. Sustained dosing of drugs holds immense significance for a range of industries, and hence, the use of sustained release excipients has become more pronounced in recent times. Excipients for modified release help in releasing drugs at a slow pace over an extended time period,
Hand Sanitizer Market Promising Growth Opportunities and Forecast 2018 - 2028 | …
Global Hand Sanitizer Market: Overview Globally, people are now more aware about there about various diseases and are more health conscious. Increasing awareness programs about hand sanitization by various organizations such as FDA, WHO, and others and improving living standards have increased demand for hand sanitizers. According to various researches to prevent the transmission of infection, which largely caused hand transmission has also boosted the demand hand sanitizers. Moreover, proper cleanliness
Resveratrol Market Predicted to Accelerate the Growth by 2018-2028 | SiChuan Xie …
Global Resveratrol Market: Overview The rising demand from the pharmaceutical industry is likely to boost growth of the resveratrol market in coming years. Resveratrol has wide application in pharmaceutical industry owing to its healing and managing properties to treat different type of disease to argument growth of this market. Also, its properties to heal several fatal disease like cancer, diabetes, cardio-vascular disease and neurological disease to influence market growth in coming

All 5 Releases


More Releases for Infection

Shigella Infection (Shigellosis) Therapeutics- Pipeline Analysis 2018
Shigella infection, also known as shigellosis, is a bacterial infection caused by a family of bacteria known as shigella. The main symptom of this infection is diarrhea, and can be passed through direct contact with the bacteria in the stool. Download the sample report @ https://www.pharmaproff.com/request-sample/1072 The other sign and symptoms associated with shigella infection are abdominal pain, cramps, and fever. Children between the age of two and four years are
Infection Prevention and Control
Infection control products and accessories aids in the prevention and control of hospital associated & other healthcare infections. These products range from disinfectants to sterilization equipment used in the healthcare settings. Infections needs to be controlled while injecting the drugs, during the surgery and hospital stay of a patient. In addition, infection control and preventive measures aid to avoid the most common hospital infections among the healthcare staff. Get Free 10
Infection Surveillance Solutions Market Drivers With Outlook
North America is expected to hold a dominant position in global infection surveillance solutions market due to high adoption of infection surveillance solutions by hospitals in the U.S. and Canada. For instance, in 2014, Tucson Medical Center (TMC), a U.S.-based hospital installed infection surveillance solution from RL Solutions and in 2014, Trillium Health Partners, a Canada-based hospital has installed RL Solutions’ automated infection surveillance throughout its organization. Click To Continue
Influenza B Infection Market Endeavors Growth 2025
Global Influenza B Infection Market: Snapshot Influenza B infection is considered as one of the common conditions that affects a large number of people across the globe, caused due to the influenza virus B genera of the family. The condition of influenza B infection requires proper medications and treatments in order to avoid severe complications. At present, several medicines and vaccinations are made available in order to reduce the incidence of
Gram-Negative Bacterial Infection Market - Infection-type Segmentation 2017 - 20 …
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the
Infection Surveillance Solutions Market
Infection surveillance solution helps healthcare facilities in reporting patient-associated data to the state and federal authorities. Integration of infection surveillance software with already existing networks of medical facilities and hospitals is an easy process. A recent report published by Persistence Market Research (PMR) estimates the global infection surveillance solution market to register a staggering 14.04% CAGR during the forecast- 2017 to 2025. The US$ 316.67 Mn market is likely to